← Leaderboards
Xiaoqi Liu
Harvard University
$16,953,145
Attributed
$17,977,902
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,977,902 · 10
By mechanism
R01$16,971,547 · 7
K01$746,715 · 1
T32$182,426 · 1
P30$77,214 · 1
Top collaborators
- Hsin-Sheng Yang3 shared
- Isabel W Mellon2 shared
Others in their field
Top investigators on “Event”
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Francis L Halzen · University Of Wisconsin-Madison$229,314,069
Research focus
EventMalignant NeoplasmsCellsMouse ModelResistanceSignal TransductionMissionInnovationBiochemicalReceptor SignalingMalignant Neoplasm Of ProstateNovel StrategiesProstate Cancer CellAndrogen ReceptorSignal PathwayFosteringInvestigationAndrogensPatient-Focused OutcomesCastrationPhosphorylationPublic HealthCancer PatientAffect
Grant awards (57)
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer$631,310
R01 · FY2025 · CA · contact PI
Plk1 as a prognostic biomarker for prostate cancer$543,492
R01 · FY2025 · CA · contact PI
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer$515,060
R01 · FY2025 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer.$346,655
R01 · FY2025 · CA · contact PI
Overcoming Drug Resistance of Castration-Resistant Prostate Cancer$289,447
R01 · FY2025 · CA · contact PI
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer$601,289
R01 · FY2024 · CA · contact PI
Plk1 as a prognostic biomarker for prostate cancer$520,626
R01 · FY2024 · CA · contact PI
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer$470,310
R01 · FY2024 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer.$317,619
R01 · FY2024 · CA · contact PI
Overcoming Drug Resistance of Castration-Resistant Prostate Cancer$274,998
R01 · FY2024 · CA · contact PI
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer$634,489
R01 · FY2023 · CA · contact PI
Plk1 as a prognostic biomarker for prostate cancer$537,065
R01 · FY2023 · CA · contact PI
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer$485,160
R01 · FY2023 · CA · contact PI
Overcoming Drug Resistance of Castration-Resistant Prostate Cancer$289,496
R01 · FY2023 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer.$252,883
R01 · FY2023 · CA · contact PI
Plk1 as a prognostic biomarker for prostate cancer$537,065
R01 · FY2022 · CA · contact PI
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer$485,160
R01 · FY2022 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer.$339,559
R01 · FY2022 · CA · contact PI
Overcoming Drug Resistance of Castration-Resistant Prostate Cancer$289,520
R01 · FY2022 · CA · contact PI
Plk1 as a prognostic biomarker for prostate cancer$548,025
R01 · FY2021 · CA · contact PI
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer$467,258
R01 · FY2021 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer.$346,488
R01 · FY2021 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer$348,345
R01 · FY2020 · CA · contact PI
Treatment of Castration-resistant Prostate Cancer (CRPC)$348,087
R01 · FY2020 · CA · contact PI
Enhancing anti-neoplastic activity of metformin in prostate cancer$335,504
R01 · FY2020 · CA · contact PI
Overcoming drug resistance of castration-resistant prostate cancer$262,171
R01 · FY2020 · CA · contact PI
Training Grant in Molecular Mechanisms of Toxicity$75,389
T32 · FY2020 · ES · contact PI
Enhancing anti-neoplastic activity of metformin in prostate cancer$335,913
R01 · FY2019 · CA · contact PI
Treatment of Castration-resistant Prostate Cancer (CRPC)$332,580
R01 · FY2019 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer$329,881
R01 · FY2019 · CA · contact PI
Overcoming drug resistance of castration-resistant prostate cancer$244,949
R01 · FY2019 · CA · contact PI
Training Grant in Molecular Mechanisms of Toxicity$107,037
T32 · FY2019 · ES · contact PI
Cell Identity and Signaling Research Program (Project-001)$35,309
P30 · FY2019 · CA · contact PI
Enhancing anti-neoplastic activity of metformin in prostate cancer$357,717
R01 · FY2018 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer$345,987
R01 · FY2018 · CA · contact PI
Treatment of Castration-resistant Prostate Cancer (CRPC)$263,941
R01 · FY2018 · CA · contact PI
Overcoming drug resistance of castration-resistant prostate cancer$260,963
R01 · FY2018 · CA · contact PI
Treatment of Castration-resistant Prostate Cancer (CRPC)$90,622
R01 · FY2018 · CA · contact PI
Cell Identity and Signaling Research Program (Project-001)$34,438
P30 · FY2018 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer$8,576
R01 · FY2018 · CA · contact PI
Cell Identity and Signaling Research Program (Project-001)$7,467
P30 · FY2018 · CA · contact PI
Enhancing anti-neoplastic activity of metformin in prostate cancer$357,624
R01 · FY2017 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer$354,563
R01 · FY2017 · CA · contact PI
Treatment of Castration-resistant Prostate Cancer (CRPC)$354,563
R01 · FY2017 · CA · contact PI
Overcoming drug resistance of castration-resistant prostate cancer$257,688
R01 · FY2017 · CA · contact PI
Enhancing anti-neoplastic activity of metformin in prostate cancer$354,563
R01 · FY2016 · CA · contact PI
Improving chemotherapy of castration-resistant prostate cancer$354,563
R01 · FY2016 · CA · contact PI
Treatment of Castration-resistant Prostate Cancer (CRPC)$354,563
R01 · FY2016 · CA · contact PI
Overcoming drug resistance of castration-resistant prostate cancer$257,688
R01 · FY2016 · CA · contact PI
Plk1 in Chemo-resistance of Cancer$235,315
R01 · FY2013 · CA · contact PI
Plk1 in Chemo-resistance of Cancer$250,860
R01 · FY2012 · CA · contact PI
Plk1 in Chemo-resistance of Cancer$251,347
R01 · FY2011 · CA · contact PI
Functional studies of Plk1 and its interacting proteins$153,663
K01 · FY2009 · CA · contact PI
Functional studies of Plk1 and its interacting proteins$153,663
K01 · FY2008 · CA · contact PI
Functional studies of Plk1 and its interacting proteins$153,663
K01 · FY2007 · CA · contact PI
Functional studies of Plk1 and its interacting proteins$153,663
K01 · FY2006 · CA · contact PI
Functional studies of Plk1 and its interacting proteins$132,063
K01 · FY2005 · CA